Hennigsdorf, Germany 

Pantherna Therapeutics GmbH, a leader in advanced LNP technologies for mRNA-based therapeutics, is pleased to announce the grant of South Korean Patent KR 10-2811229. Issued on May 19, 2025, this new patent provides protection for the company’s proprietary PTXmRNA® technology, specifically its innovative combination of defined regulatory 5´- /3´- UTRs (untranslated regions).

This latest patent grant follows the Japanese Patent Office’s approval on April 16, 2025, underscoring the broad applicability and novelty of Pantherna’s PTXmRNA® technology for robust expression of therapeutic proteins.

Ansgar Santel, Chief Executive Officer of Pantherna Therapeutics, stated: “Securing intellectual property protection in South Korea, in addition to our recently granted Japanese patent, marks another significant milestone for Pantherna Therapeutics. These grants collectively bolster our position in key Asian markets and reinforce the global recognition of our PTXmRNA® technology’s innovative potential.”